一例肾癌肌肉及头皮转移案例
Renal Cell Carcinoma with Muscle and Scalp Metastases: A Case Report
DOI: 10.12677/ACM.2023.133692, PDF,   
作者: 赵文铄:青岛大学医学院,山东 青岛;李延江*:青岛大学医学院附属医院泌尿外科,山东 青岛
关键词: 转移性肾癌免疫治疗靶向治疗Metastatic Renal Cell Carcinoma Immunotherapy Targeted Therapy
摘要: 肾癌是泌尿外科肿瘤中常见的一类恶性肿瘤,主要病理类型有肾透明细胞癌、乳头状细胞癌、嫌色细胞癌等,以肾透明细胞癌最为常见,占成人肾恶性肿瘤的70%~80%,传统的肾癌“三联征”:血尿、疼痛、腹部肿块,随着医疗水平的不断提高,以及人们体检意识的增强已经不再常见,大多数出现肾癌三联征的患者多处在肿瘤晚期。约20%~30%的患者就诊时已出现转移,并且这一部分患者的5年生存率较低。肾癌远处转移部位以淋巴结、肺、骨、脑、肝脏等常见,而肾癌伴肌肉及头皮转移少见。本文报道了一例肾癌术后并发肌肉、头皮转移的案例,并对患者的个性化治疗方案进行讨论。
Abstract: Renal Cell Carcinoma is a common malignant tumor in urologic surgery, the main pathological types include clear cell carcinoma of kidney, papillary cell carcinoma, chromophobe cell carcinoma, etc. Clear cell carcinoma of kidney is the most common, accounting for 70%~80% of adult renal malig-nant tumors. The traditional “triad” of renal cell carcinoma is as follows: Hematuria, pain and ab-dominal mass are no longer common with the continuous improvement of medical level and the enhancement of people’s awareness of physical examination. Most patients with renal cell carcino-ma triad are mostly in the advanced stage of tumor. About 20%~30% of patients have metastases at the time of visit, and the 5-year survival rate of these patients is low. Lymph nodes, lung, bone, brain, liver and other distant metastatic sites of renal cancer are common, but renal cancer with muscle and scalp metastasis is rare. In this paper, we report a case of renal carcinoma complicated with muscle and scalp metastasis after surgery, and discuss the individualized treatment of the pa-tient.
文章引用:赵文铄, 李延江. 一例肾癌肌肉及头皮转移案例[J]. 临床医学进展, 2023, 13(3): 4845-48520. https://doi.org/10.12677/ACM.2023.133692

参考文献

[1] Ljungberg, B., et al. (2019) European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology, 75, 799-810. [Google Scholar] [CrossRef] [PubMed]
[2] 王宁, 李明义, 杨培谦. 肾癌预后分析系统概述[J]. 中国医刊, 2016, 51(9): 26-28. [Google Scholar] [CrossRef
[3] Singh, D. (2021) Current Updates and Future Perspec-tives on the Management of Renal Cell Carcinoma. Life Sciences, 264, Article ID: 118632. [Google Scholar] [CrossRef] [PubMed]
[4] 马巍巍, 王龙信. 转移性肾癌免疫治疗的新进展[J]. 国际泌尿系统杂志, 2022, 42(2): 349-352.
[5] 熊斌, 鲁伟. 转移性肾癌治疗的现状和进展[J]. 中华泌尿外科杂志, 2021, 42(4): 308-311.
[6] Abe, H. and Kamai, T. (2013) Recent Advances in the Treatment of Metastatic Renal Cell Carci-noma. International Journal of Urology, 20, 944-955. [Google Scholar] [CrossRef] [PubMed]
[7] Brady, L.W., O’Neill, E.A. and Farber, S.H. (1997) Unusual Sites of Metastases. Seminars in Oncology, 4, 59-64.
[8] Lew, M., Foo, W.-C. and Roh, M.H. (2014) Diagnosis of Metastatic Renal Cell Carcinoma on Fine-Needle Aspiration Cytology. Archives of Pathology & Laboratory Medicine, 138, 1278-1285. [Google Scholar] [CrossRef
[9] Motzer, R.J., Nanus, D.M., Russo, P. and Berg, W.J. (1997) Renal Cell Carcinoma. Current Problems in Cancer, 21, 185-232. [Google Scholar] [CrossRef
[10] Jantzer, P. and Schendel, D.J. (1998) Human Renal Cell Carcinoma Antigen-Specific CTLs: Antigen-Driven Selection and Long-Term Persistence in Vivo. Cancer Research, 58, 3078-3086.
[11] Clark, P.E. (2009) The Role of VHL in Clear-Cell Renal Cell Carcinoma and Its Relation to Targeted Therapy. Kidney International, 76, 939-945. [Google Scholar] [CrossRef] [PubMed]
[12] Malhotra, K.P., Gupta, A., Shukla, S., Agarwal, G.R. and Malhotra, H.S. (2021) Metastases from Renal Cell Carcinoma—Report of Three Unpre-dictable Cases and Literature Review. Indian Journal of Cancer, 58, 273-277.
[13] 周莉, 盛锡楠. 晚期肾癌的免疫治疗进展与述评[J]. 肿瘤防治研究, 2020, 47(3): 149-153. [Google Scholar] [CrossRef
[14] Braun, D.A., et al. (2021) Beyond Conventional Im-mune-Checkpoint Inhibition—Novel Immunotherapies for Renal Cell Carcinoma. Nature Reviews Clinical Oncology, 18, 199-214. [Google Scholar] [CrossRef] [PubMed]
[15] Hirsch, L., Flippot, R., Escudier, B. and Albiges, L. (2020) Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma. Drugs, 80, 1169-1181. [Google Scholar] [CrossRef] [PubMed]
[16] McKay, R.R., Bossé, D. and Choueiri, T.K. (2018) Evolving Systemic Treatment Landscape for Patients with Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 36, 3615-3623. [Google Scholar] [CrossRef
[17] Rini, B.I., et al. (2019) Atezolizumab plus Bevacizumab versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (Immotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial. Lancet, 393, 2404-2415. [Google Scholar] [CrossRef